TrumpRx and the January 2026 GLP-1 Price Cut: A Buyer's Guide to $245 Wegovy, $149 Pills, and Real Out-of-Pocket Costs

On November 6, 2025, President Trump announced a landmark pricing agreement with Eli Lilly and Novo Nordisk that cuts the price of the four blockbuster GLP-1 drugs — Ozempic and Wegovy (Novo, semaglutide) plus Mounjaro and Zepbound (Lilly, tirzepatide) — for Americans buying through Medicare, Medicaid, and a new government-run direct-to-consumer platform called TrumpRx.

Starting doses on TrumpRx will be $350 per month at launch, dropping to $245 per month over a two-year period. Medicare prices for the four drugs will be $245 per month, with Medicare beneficiaries paying a $50 copay. Upcoming obesity pills — Lilly's Foundayo (orforglipron, approved April 2026) and Novo's Wegovy pill (oral semaglutide 25/50 mg, launched January 2026) — will cost $149 per month across Medicare, Medicaid, and TrumpRx.

Medicare will also cover Wegovy and Zepbound for obesity with related comorbidities for the first time. Medicare Part D has historically excluded coverage of anti-obesity drugs by statute, and the new agreement carves out this class specifically. The change is a substantial expansion for the estimated 15 million Medicare beneficiaries with obesity who would qualify for coverage.

TrumpRx.gov is scheduled to launch in January 2026. As of September 2, 2026, the platform is on schedule per Health and Human Services and Centers for Medicare & Medicaid Services updates. This piece walks through the price you pay under each type of coverage, what compounded-GLP-1 users should think about, and the practical timing questions people are asking their prescribers right now.

The core of the deal is a Most Favored Nation (MFN) pricing framework — the idea that Americans should pay no more than what patients in other developed countries pay. Lilly and Novo agreed to guarantee MFN prices on all new medications going forward, repatriate increased foreign revenue on existing products, and make MFN prices available to all state Medicaid programs.

Injectable GLP-1 pricing. Starting doses of Wegovy and Zepbound on TrumpRx will be $350 per month at launch, trending down to $245 per month over a two-year period. Medicare prices for Ozempic, Wegovy, Mounjaro, and Zepbound will be $245 per month. This is a substantial drop from the pre-deal list prices of $1,349 per month (Wegovy) and $1,059 per month (Zepbound), though most patients with commercial insurance were already paying less than list through manufacturer coupons and coverage negotiations.

Oral GLP-1 pricing. Upcoming oral obesity drugs — Eli Lilly's Foundayo (orforglipron) that was FDA-approved April 1, 2026, and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg) that launched January 2026 — will cost $149 per month across Medicare, Medicaid, and TrumpRx. Higher doses may cost up to $399 per month. Foundayo, if it stays at $149 for starting doses, would be substantially cheaper than any injectable option.

Medicare Part D coverage expansion. Medicare Part D has historically excluded coverage of drugs used for weight loss under statute dating to 2003. The new deal creates a coverage carve-out for GLP-1 drugs used for obesity when patients also have related comorbidities (type 2 diabetes, cardiovascular disease, sleep apnea, chronic kidney disease). Medicare beneficiaries who qualify will pay a $50 copay per month for injectable GLP-1s.

Medicaid coverage. All 50 state Medicaid programs will now have access to MFN pricing on GLP-1s. Individual states retain the authority to decide which drugs to cover under their formularies, and coverage for obesity indication versus diabetes indication varies by state. States that had previously declined obesity coverage due to cost pressure will now face a lower budget impact if they choose to add it.

Commercial insurance. The deal does not directly regulate commercial insurance pricing. Employer-sponsored and individually-purchased commercial plans will continue to negotiate their own pricing with Lilly and Novo. The likely effect is downward pressure on commercial GLP-1 pricing as manufacturers align their negotiations with the MFN framework, but this will play out over the next 12 to 24 months.

The price you pay depends on your specific coverage. A practical grid, as of September 2026 per HHS and CMS communications:

Medicare Part D beneficiaries with obesity plus a qualifying comorbidity. $50 per month copay for injectable Wegovy, Zepbound, Ozempic, or Mounjaro. Coverage kicks in mid-2026 as CMS finalizes formulary guidance. Enrollment in Part D is required.

Medicare Part D beneficiaries with type 2 diabetes but no obesity indication. Ozempic and Mounjaro have been covered under Part D for diabetes since their original approvals. The new deal reduces net cost to Medicare and drops the negotiated price to $245 per month, but copays for diabetes-indicated prescriptions were already relatively low and vary by plan.

Medicaid beneficiaries. State-by-state variation. Adult obesity coverage is now available at MFN pricing for states that choose to cover the class. Copays are typically $0 to $8 per month. Check with your state Medicaid program for current coverage rules.

Commercially-insured patients with GLP-1 obesity coverage. Commercial pricing will continue to depend on the specific plan. Employers who cover Wegovy or Zepbound for obesity typically negotiate net prices somewhere between $500 and $900 per month; patients pay copays in the $25 to $100 range at retail pharmacy. The MFN framework may pressure these prices lower over time.

Commercially-insured patients without GLP-1 obesity coverage. If your employer's plan excludes obesity drugs, you can either pay retail with a manufacturer coupon (Wegovy list is $1,349 but coupon programs offer $499 for uninsured or non-covered cash-pay) or use TrumpRx starting January 2026 at $350 per month (trending to $245).

Uninsured or cash-pay patients. TrumpRx is designed specifically for this group. Starting January 2026, $350 per month for injectable starting doses; $149 per month for the oral obesity pills. Manufacturer direct-to-consumer programs (NovoCare, LillyDirect) continue at $499 per month for cash-pay Wegovy and Zepbound as of September 2026 and will likely align with TrumpRx pricing over 2026.

Patients currently on compounded semaglutide or tirzepatide. The pricing calculus changes substantially. Compounded GLP-1s from telehealth vendors have averaged $200 to $400 per month depending on the vendor. The FDA closed the shortage-based compounding pathway in Q1 2025, and enforcement has ramped up. If TrumpRx and Medicare pricing land as announced, the price gap between branded and compounded is narrowing quickly. More on this below.

TrumpRx.gov is a government-facilitated direct-to-consumer purchasing platform for GLP-1 drugs and other medications selected by the administration. As of September 2, 2026, per HHS communications, the platform is scheduled to launch in January 2026 with the following features:

Product scope. At launch, Wegovy, Zepbound, Ozempic, Mounjaro, plus the newer oral products Foundayo (orforglipron) and Wegovy pill. Additional medications will be added over 2026, potentially including insulin and other high-cost brand-name drugs where Lilly and Novo have pricing agreements.

Purchase process. Patients register on the platform, upload a valid prescription from a licensed U.S. prescriber, and pay the listed price. Shipping is direct to the patient's address. Patients do not need to have insurance to use the platform.

Prescription requirement. A valid prescription from a state-licensed clinician is required. TrumpRx does not itself prescribe. Patients who do not have a current prescription will need to obtain one — either from their existing primary care provider, a specialist, a telehealth service that provides consultations, or through prescriber networks that TrumpRx may partner with.

Manufacturer supply. Novo Nordisk and Eli Lilly supply the medications directly to TrumpRx for distribution. The supply arrangement is separate from retail pharmacy channels, so a Wegovy shortage at your local CVS does not necessarily mean a Wegovy shortage on TrumpRx (though shortages can affect the manufacturer's total supply and cascade to all channels).

Payment. Credit and debit cards, plus Health Savings Account (HSA) and Flexible Spending Account (FSA) cards are expected to be accepted. HSA/FSA eligibility depends on the specific plan; check with your account administrator.

Not covered by TrumpRx. Compounded formulations, drugs from other manufacturers not part of the agreement, and drugs prescribed for off-label uses that fall outside the platform's approved indications. TrumpRx is not intended to be a full pharmacy replacement — it is a specific channel for specific negotiated products.

What is not yet clear. As of September 2026, several practical details remain in development or subject to change. Whether TrumpRx will accept Medicaid or Medicare directly, whether patients can be reimbursed through their commercial insurance, how the platform handles international shipping (or blocks it), and how prescription verification will be validated in real time. The January launch is expected to answer most of these questions.

Different pieces of the deal take effect at different times. A rough timeline as of September 2, 2026:

Now (September-December 2026). Medicare Part D coverage of GLP-1s for obesity is being finalized by CMS through the plan-year 2026 formulary process. Part D plans are updating their formularies to include obesity-indicated GLP-1s at the negotiated $245 monthly price with $50 copays. Beneficiaries will see these updates reflected in their 2026 plan benefit letters, typically mailed by October 2026 for the January 1, 2026 plan year.

January 2026. TrumpRx.gov launches. First shipments to patients begin. Medicare Part D obesity coverage takes effect for 2026 plan year enrollees. State Medicaid programs that elected to add or expand GLP-1 obesity coverage for 2026 will have their new formularies in effect.

January-June 2026. Ramp period. TrumpRx builds distribution capacity, refines the prescription verification process, and adds product lines. Commercial insurance renewals for 2026 plan year reflect updated negotiated pricing where employers have re-negotiated.

Mid-to-late 2026. TrumpRx pricing trends down from $350 to $245 for starting doses over the two-year adjustment period, per the agreement structure. Watch for HHS confirmation of the specific step-down dates.

Ongoing through 2028. MFN price harmonization continues for existing drugs and new approvals. Retatrutide (Lilly's next-generation triple agonist), if approved in 2027-2028, would launch under MFN framework from the start.

What patients starting GLP-1 therapy now should do. If you are considering starting Wegovy or Zepbound in the next 3 months, the questions to work through with your prescriber and insurance are: (1) Does my current plan cover the drug at all, and what would my copay be if I started now? (2) Would waiting until January 2026 to start via TrumpRx or Medicare Part D save enough to justify the delay? (3) Is my prescriber willing to give me a prescription valid for TrumpRx use, or will I need a new prescription then? Most patients with existing commercial coverage will find that starting now with existing benefits is fine, but the specific numbers depend on the specific plan.

Roughly 1 million Americans have used compounded semaglutide or tirzepatide from telehealth vendors and wellness clinics, based on estimates from IQVIA and market research firms. The FDA closed the shortage-based compounding pathway in early 2025 as Wegovy and Zepbound came off the shortage list, and enforcement against non-compliant compounders has increased throughout 2026.

The January 2026 TrumpRx launch, plus the Medicare Part D obesity coverage expansion, changes the practical calculation for many compounded users. A few scenarios:

Currently paying $199-299 per month for compounded semaglutide from a telehealth vendor. TrumpRx at $350 (dropping to $245) is close in price to what you are paying and offers verified pharmaceutical-grade product, a legal supply chain, and manufacturer-supported product. The gap is now small enough that many users are switching. If you have Medicare Part D or Medicaid, your out-of-pocket may be substantially lower.

Currently paying $99-149 per month for compounded semaglutide from a low-cost vendor. The gap is larger, and some low-cost vendors will continue to compete on price with branded. The regulatory risk is also larger, since low-cost compounded product is more likely to come from operations that are not fully compliant with 503A (small-scale patient-specific compounding) or 503B (outsourcing-facility) pharmacy standards. Product identity, purity, and potency are more variable, and FDA enforcement has focused on this segment.

Currently using compounded tirzepatide because your insurance does not cover Zepbound. Medicare or Medicaid coverage of Zepbound at $50 copay is a substantial improvement if you qualify. Commercial coverage may improve over the next year as MFN pricing pressures negotiations. TrumpRx at $350 (trending to $245) is a legal cash-pay option.

Currently using compounded semaglutide at higher doses than the FDA has approved. Wegovy's newly-approved 7.2 mg dose (approved March 19, 2026) provides an FDA-approved high-dose option for the first time. This is relevant for patients who had moved to compounded 3.0-5.0 mg doses seeking more weight loss than 2.4 mg produced.

Practical framework. If you are considering switching from compounded to branded, the questions are: What is my actual price on TrumpRx or via my insurance? What supply, tolerability, and prescriber support do I get with the branded product versus my current vendor? Is the regulatory risk of continuing on compounded material enough to justify a switch even if the price is somewhat higher? Individual answers vary.

A note on the ongoing compounding debate. The FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend six other peptides (not GLP-1s) for the 503A bulk drug substances list. The GLP-1 shortage-based compounding pathway remains closed. Compounded GLP-1s are legally allowed only under narrow circumstances (personalized dosing for specific medical needs, generally not for general obesity treatment). Enforcement is ongoing.

The pricing landscape is complicated enough that a prescriber conversation is worth having before making major decisions. Concrete questions to ask, framed around common situations:

"I want to start a GLP-1 for obesity. Should I wait until January to use TrumpRx, or start now with my current insurance?" The answer depends on your specific coverage. If your commercial insurance covers Wegovy or Zepbound at $50-100 per month, starting now is probably fine. If your insurance excludes obesity drugs and you would be paying $500+ per month cash, waiting for TrumpRx may make sense.

"I'm on Wegovy through commercial insurance for $75 per month. What happens to my price if TrumpRx and MFN pricing takes effect?" Commercial pricing is not directly regulated by the deal, so your $75 copay may not change immediately. Over time, as employer plans re-negotiate, you may see stable or slightly lower prices.

"I'm on Medicare and my Wegovy prescription has always been cash-pay because Medicare doesn't cover obesity drugs. When does that change?" Starting with the 2026 Medicare Part D plan year (January 2026), obesity-indicated GLP-1s are covered for beneficiaries with qualifying comorbidities at $50 monthly copay. Confirm your plan's formulary and copay tier in your 2026 plan benefit letter (mailed by October 2026).

"I'm on compounded semaglutide from a telehealth vendor. Should I switch to Wegovy on TrumpRx?" Depends on the price gap, your access to the telehealth vendor going forward, and your regulatory risk tolerance. Discuss with your prescriber whether they can convert your compounded prescription to a Wegovy prescription valid for TrumpRx use.

"I take Ozempic for type 2 diabetes and am worried the price cut means Novo will stop making it." The pricing agreement includes commitments to supply. Ozempic and Mounjaro production for the diabetes market has been the priority throughout the shortage period, and this is not likely to change. Ask specifically about your local pharmacy's stocking situation.

"When would Foundayo (orforglipron pill) be a better option for me than Wegovy injection?" Foundayo was FDA-approved April 1, 2026 for obesity. Pill preference over injection depends on tolerability profile, effectiveness relative to your treatment goals, and price. At $149 per month on the announced pricing framework, Foundayo may be the most affordable option for cash-pay patients starting in January 2026.

A few pieces of the picture are not yet fully clear as of September 2026, and would affect the practical calculation for specific patients.

Commercial insurance response. The deal does not directly bind commercial insurance. Whether employer plans align to the MFN framework, keep current pricing, or move in mixed ways will play out over the next 12 to 24 months.

Exact TrumpRx step-down schedule. The $350-to-$245 trajectory over two years has not been broken into specific dates. Prices could adjust quarterly, semi-annually, or in a single step; HHS has not confirmed.

Prescription verification standards. How TrumpRx validates prescriptions, whether it accepts prescriptions from any state-licensed prescriber or only from a subset, and how it handles state-by-state variations in telehealth prescribing rules is still being finalized.

Foundayo formulary tier. Whether Medicare Part D plans will place Foundayo on preferred tiers versus specialty tiers affects the actual copay. The $149 negotiated price is a manufacturer commitment; plan-specific benefit design determines what the patient sees.

Retatrutide pricing. Lilly's next-generation triple agonist retatrutide is expected to file with the FDA in 2027 and could launch in 2027-2028. If the MFN framework applies, retatrutide would launch at MFN pricing rather than a premium pricing model. Whether Lilly will price at parity with Zepbound or higher given the higher weight loss (28%+ in Phase 3) is not clear yet.

International shipping. TrumpRx is designed for U.S. patients with U.S. shipping addresses. Whether U.S. citizens abroad or short-term visitors can use it is not confirmed.

Compounded GLP-1 regulatory outlook. The FDA continues to enforce against non-compliant compounders. Whether this enforcement will drive most compounded users to switch, or whether a compliant compounding market for personalized doses will persist, is playing out through 2026.

The November 2025 pricing agreement between the Trump administration and Eli Lilly plus Novo Nordisk cuts the price of injectable GLP-1s to $245 per month for Medicare beneficiaries and TrumpRx cash-pay users (after a two-year step-down from $350), and prices oral obesity pills at $149 per month. Medicare Part D will cover GLP-1s for obesity plus qualifying comorbidities for the first time, with a $50 monthly copay.

TrumpRx.gov launches in January 2026 as a government-facilitated direct-to-consumer platform. Patients need a valid U.S. prescription and can pay cash or with an HSA/FSA card. The platform is not a full pharmacy replacement; it is a specific channel for specific negotiated products.

Who pays what depends on the specific coverage: $50 copay for Medicare Part D beneficiaries with obesity plus comorbidities, state-dependent copays for Medicaid, negotiated prices for commercial plans, and $350 (trending to $245) for uninsured or cash-pay purchases through TrumpRx.

For patients currently on compounded GLP-1s, the January 2026 launch narrows the price gap between compounded and branded product. Switching decisions depend on the specific compounded vendor, current price, regulatory risk tolerance, and access to a prescriber willing to write a branded prescription.

Several practical details — commercial insurance response, exact step-down timing, prescription verification standards, and Foundayo formulary placement — will be clearer once TrumpRx launches and the 2026 Medicare Part D plan year takes effect. For most patients, the questions to work through with a prescriber and insurance are: what is my actual out-of-pocket cost under each option available to me, and does waiting for January make sense given my specific situation?